BiologicalCombination product
Sabestomig clinical trials
Also written AZD7789.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2021 (1)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Presage Biosciences (2) · AstraZeneca (1)
Often tested with
Tested in the same studies.
Rilvegostomig (2) · Volrustomig (2) · Pembrolizumab (2) · Tilatamig samrotecan (2)
Studies
Open first, then newest update. How each study uses sabestomig is read from its arms, and is right about nine times in ten.
Testing it · 3
- PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCCCompletedEarly Phase 1Presage BiosciencesNCT06366451Written as Sabestomig
- Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesActive, not recruitingEarly Phase 1Presage BiosciencesNCT04541108Written as Sabestomig
- Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin LymphomaCompletedPhase 1AstraZenecaNCT05216835Written as Sabestomig (AZD7789)
Codes
What other systems call sabestomig · ClinicalTrials.gg INT018439
- UNII (FDA) X79QP2R2CZSABESTOMIGOne source FDA
- NCI Thesaurus C199016SabestomigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | X79QP2R2CZ | SABESTOMIG | One source FDA |
| NCI Thesaurus | C199016 | Sabestomig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.